ArticleFrontiers in microbiology2018
Autoprobiotics as an Approach for Restoration of Personalised Microbiota.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Trial
- Enterococcal autoprobiotics in the complex treatment of colorectal cancer patient receiving chemotherapy: Two case reports and review of literature.World journal of clinical cases · 2025Article
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period.Microorganisms · 2024Article
- Restoration ofInternational journal of molecular sciences · 2024Article
- Probiotics and autoprobiotics for treatment ofWorld journal of clinical cases · 2023Review
- Female reproductive tract-organ axes.Frontiers in immunology · 2023Review
- Consortium of Indigenous Fecal Bacteria in the Treatment of Metabolic Syndrome.Microorganisms · 2022Article
- Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome.International journal of molecular sciences · 2022Article
- Aging gut microbiota of wild macaques are equally diverse, less stable, but progressively personalized.Microbiome · 2022Article
- Gastrointestinal microbiome andWorld journal of gastroenterology · 2022Article
- Lactobacilli: Legal Regulation and Prospects for New Generation Drugs.Applied biochemistry and microbiology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human microbiota is a complex consortium of microorganisms involved in the proper functioning of almost every system of the organism. Majority of the human diseases are associated with the development of intestinal dysbiosis. Dysbiotic condition or dysbiosis is a key pathogenic condition causing many severe infectious or non-infectious diseases. Rapid return to the original microbiota in many cases leads to the fast recovery from the disease. However, the optimal way of the treatment of dysbiosis is still under the discussion. Recently we have developed a method of autoprobiotics based on using isolated indigenous bacteria for improving of microbiota condition. The method based on feeding the patients with bacterial products grown from their personal, genetically characterised strains have been successfully tested in clinic on patients with IBS or chronic pneumonia. In present study we tried to evaluate technology employing autoprobiotic bacteria belonging to different species employing the rat model of antibiotic induced dysbiosis. Six experimental groups of animals after taking antibiotics were treated with different variants of autoprobiotics (lactobacillus, bifidobacteria, enterococcus, their mixture, fecal microbiota, or anaerobically grown complex of indigenous microbiota) prepared for each of them before the development of dysbiosis. Judging by the multiple parameters including metagenomics analysis of microbiota, immune status and microbiota content of the animals with dysbiosis relatively to control group, the most pronounced positive changes were provided by autoprobiotics based on enterococci, bifidobacteria or the consortium of indigenous bacteria grown under anaerobic conditions. These groups of autoprobiotics were delivering the most effective restoration of the original microbiota content and significant anti-inflammatory reaction of the immune system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.